Proteomics of bronchial biopsies: Galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients

Immunology Letters

Volumn 162, Issue 1, 2014, Pages 2-10

  Mauri, Pierluigi ^a   Riccio, Anna Maria ^b   Rossi, Rossana ^a   Di Silvestre, Dario ^a   Benazzi, Louise ^a   De Ferrari, Laura ^b   Negro, Roberto Walter Dal ^c   Holgate, Stephen T ^d   Canonica, Giorgio Walter ^b  

^a INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c CMS   (Italy)

^d SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Galectin 3; Interactome; Omalizumab; Proteomics analysis; Severe asthma

Indexed keywords

ACTIN RELATED PROTEIN; ALPHA TROPOMYOSIN; CALMODULIN; CALMODULIN 3; COLLAGEN 1 ALPHA 1; COLLAGEN 6 ALPHA 1; COLLAGEN 6 ALPHA 3; COLLAGEN ALPHA 1; COLLAGEN ALPHA 2; COLLAGEN TYPE 1; DESMIN; ELASTIN; EZRIN; FIBULIN; FIBULIN 2; FIBULIN 5; GALECTIN 3; MYOSIN; MYOSIN 11; MYOSIN 9; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN 6; OMALIZUMAB; PERLECAN; PLATELET DERIVED GROWTH FACTOR B; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VIMENTIN; VINCULIN; ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; PROTEOME;

ADULT; AIRWAY REMODELING; ARTICLE; BRONCHUS BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PREVALENCE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SEVERE PERSISTENT ASTHMA; TREATMENT RESPONSE; UPREGULATION; ASTHMA; BIOPSY; BRONCHUS; CLUSTER ANALYSIS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; ODDS RATIO; PATHOLOGY; PROGNOSIS; PROTEOMICS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AIRWAY REMODELING; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; BIOMARKERS; BIOPSY; BRONCHI; CLUSTER ANALYSIS; FEMALE; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; ODDS RATIO; OMALIZUMAB; PROGNOSIS; PROTEIN INTERACTION MAPS; PROTEOME; PROTEOMICS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84908278609     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.08.010     Document Type: Article

References (42)

1. Bel E.H. Clinical practice. Mild asthma. N Engl J Med 2013, 369:549-570.
2. Holgate S.T., Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006, 368:780-793.
3. Global Initiative for Asthma (GINA) The global strategy for asthma management and prevention 2012, http://www.ginasthma.org/ (date last updated 2012).
4. Humbert M., Beasley R., Ayres J., Slavin R., Hébert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316.
5. Walker S., Monteil M., Phelan K., Lasserson T.J., Walters E.H. Anti-IgE for chronic asthma in adults and children. CDS Rev 2004, 3:CD003559.
6. Buhl R., Hanf G., Solèr M., Bensch G., Wolfe J., Everhard F., et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002, 20:1088-1094.
7. Hamburg M.A., Collins F.S. The path to personalized medicine. N Engl J Med 2010, 363:301-304.
8. Braido F., Holgate S., Canonica G.W. From "blockbusters" to "biosimilars": an opportunity for patients, medical specialists and health care providers. Pulm Pharmacol Ther 2012, 25:483-486.
9. Holgate S.T. Trials and tribulations in identifying new biologic treatments for asthma. Trends Immunol 2012, 33:238-246.
10. Corren J., Lemanske R.F., Hanania N.A., Korenblat P.E., Parsey M.V., Arron J.R., et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011, 365:1088-1098.
11. Hanania N.A., Alpan O., Hamilos D.L., Condemi J.J., Reyes-Rivera I., Zhu J., et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011, 154:573-582.
12. Manuyakorn W., Howarth P.H., Holgate S.T. Airway remodelling in asthma and novel therapy. Asian Pac J Allergy Immunol 2013, 31:3-10.
13. Bourdin A., Neveu D., Vachier I., Paganin F., Godard P., Chanez P. Specificity of basement membrane thickening in severe asthma. J Allergy Clin Immunol 2007, 119:1367-1374.
14. Riccio A.M., Dal Negro R.W., Micheletto C., De Ferrari L., Folli C., Chiappori A., et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol 2012, 25:475-484.
15. Pepe C., Foley S., Shannon J., Lemiere C., Olivenstein R., Ernst P., et al. Differences in airway remodeling between subjects with severe and moderate asthma. J Allergy Clin Immunol 2005, 116:544-549.
16. Wenzel S.E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012, 18:716-725.
17. Wheelock A.M., Wheelock C.E. Trials and tribulations of 'omics data analysis: assessing quality of SIMCA-based multivariate models using examples from pulmonary medicine. Mol Biosyst 2013, 9:2589-2596.
18. Link A.J., Eng J., Schieltz D.M., Carmack E., Mize G.J., Morris D.R., et al. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 1999, 17:676-682.
19. Park S.K., Venable J.D., Xu T., Yates J.R. A quantitative analysis software tool for mass spectrometry-based proteomics. Nat Methods 2008, 5:319-322.
20. Brambilla F., Lavatelli F., Di Silvestre D., Valentini V., Rossi R., Palladini G., et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012, 119:1844-1847.
21. Monti M., Zanoni A., Calligaro A., Ko M.S., Mauri P., Redi C.A. Developmental arrest and mouse antral not-surrounded nucleolus oocytes. Biol Reprod 2013, 88:2.
22. Hsia C.C., Hyde D.M., Ochs M., Weibel E.R. An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. Am J Respir Crit Care Med 2010, 181:394-418. ATS/ERS Joint Task Force on Quantitative Assessment of Lung Structure.
23. Villaggio B., Soldano S., Cutolo M. 1,25-Dihydroxyvitamin D3 downregulates aromatase expression and inflammatory cytokines in human macrophages. Clin Exp Rheumatol 2012, 30:934-938.
24. Nomura E., Katsuta K., Ueda T., Toriyama M., Mori T., Inagaki N. Acid-labile surfactant improves in-sodium dodecyl sulfate polyacrylamide gel protein digestion for matrix-assisted laser desorption/ionization mass spectrometric peptide mapping. J Mass Spectrom 2004, 39:202-207.
25. Mauri P., Dehò G. A proteomic approach to the analysis of RNA degradosome composition in Escherichia coli. Methods Enzymol 2008, 447:99-117.
26. Carvalho P.C., Hewel J., Barbosa V.C., Yates J.R. Identifying differences in protein expression levels by spectral counting and feature selection. Genet Mol Res 2008, 7:342-356.
27. Hilario M., Kalousis A. Approaches to dimensionality reduction in proteomic biomarker studies. Brief Bioinform 2008, 9:102-118.
28. Jain A.K., Murthy M.N., Flynn P.J. Data clustering: a review. ACM Comput Surv 1999, 31:264-323.
29. Zhao Y., Karypis G. Data clustering in life sciences. Mol Biotechnol 2005, 31:55-80.
30. Avila-Campillo I., Drew K., Lin J., Reiss D.J., Bonneau R. BioNetBuilder: automatic integration of biological networks. Bioinformatics 2007, 23:392-393.
31. Shannon P., Markiel A., Ozier O., Baliga N.S., Wang J.T., Ramage D., et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003, 13:2498-2504.
32. Maere S., Heymans K., Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 2005, 21:3448-3449.
33. Bader G.D., Hogue C.W. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform 2003, 4:2.
34. Cortegano I., del Pozo V., Cárdaba B., de Andrés B., Gallardo S., del Amo A., et al. Galectin-3 down-regulates IL-5 gene expression on different cell types. J Immunol 1998, 161:385-389.
35. López E., Zafra M.P., Sastre B., Gámez C., Lahoz C., del Pozo V. Gene expression profiling in lungs of chronic asthmatic mice treated with galectin-3: downregulation of inflammatory and regulatory genes. Mediators Inflamm 2011, 823279.
36. Sanchez-Cuellar S., de la Fuente H., Cruz-Adalia A., Lamana A., Cibrian D., Giron R.M., et al. Reduced expression of galectin-1 and galectin-9 by leucocytes in asthma patients. Clin Exp Immunol 2012, 170:365-374.
37. Ge X.N., Bahaie N.S., Kang B.N., Hosseinkhani M.R., Ha S.G., Frenzel E.M., et al. Allergen-induced airway remodeling is impaired in galectin-3-deficient mice. J Immunol 2010, 185:1205-1214.
38. Gould H.J., Sutton B.J. IgE in allergy and asthma today. Nat Rev Immunol 2008, 8:205-217.
39. Kim B., Eggel A., Tarchevskaya S.S., Vogel M., Prinz H., Jardetzky T.S. Accelerated disassembly of IgE-receptor complexes by a disruptive macromolecular inhibitor. Nature 2012, 491:613-617.
40. Henderson N.C., Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009, 230:160-171.
41. Roth M., Zhong J., Zumkeller C., S'ng C.T., Goulet S., Tamm M. The role of IgE-receptors in IgE-dependent airway smooth muscle cell remodelling. PLOS ONE 2013, 8:e56015.
42. Loftheim H., Midtvedt K., Hartmann A., Reisæter A.V., Falk P., Holdaas H., et al. Urinary proteomic shotgun approach for identification of potential acute rejection biomarkers in renal transplant recipients. Transplant Res 2012, 1:9.